KEAP1 and cancer: Additionally, these findings are of particular medical relevance as the ability to shutdown NRF2 activity, independently from KEAP1, is of particular clinical interest for cancers where activated NRF2 contributes to both the severity and resistance to treatment by radiation- or chemo-based therapies.